<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Interim CDC recommendations for COVID-19 vaccine administration errors and deviations</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Interim CDC recommendations for COVID-19 vaccine administration errors and deviations</h1>
<div class="graphic"><div class="figure"><div class="ttl">Interim CDC recommendations for COVID-19 vaccine administration errors and deviations</div><div class="cntnt"><table cellspacing="0"><colgroup span="1" width="20%"></colgroup> <colgroup span="2" width="40%"></colgroup> <tbody> <tr> <td class="subtitle1">Type</td> <td class="subtitle1">Administration error/deviation</td> <td class="subtitle1">Interim recommendation</td> </tr> <tr> <td rowspan="2">Site/route</td> <td> <ul> <li>Incorrect site (ie, site other than the deltoid muscle or vastus lateralis muscle)</li> </ul> </td> <td> <ul> <li>Do not repeat dose.</li> </ul> </td> </tr> <tr> <td> <ul> <li>Incorrect route (eg, subcutaneous)</li> </ul> </td> <td> <ul> <li>Do not repeat dose.</li> <li>Inform the recipient of the potential for local and systemic adverse events.</li> </ul> </td> </tr> <tr class="highlight_lght_gray_text"> <td rowspan="2">Age</td> <td> <ul> <li>Unauthorized age group (recipients younger than age 6 months)</li> </ul> </td> <td> <ul> <li>Do not give another dose at this time.*</li> </ul> </td> </tr> <tr class="highlight_lght_gray_text"> <td> <ul> <li>Recipients transitioning from age 4 years to 5 years during the primary series who start a 3-dose Pfizer-BioNTech series with the product for ages 6 months to 4 years (maroon cap and label border) and incorrectly receive the product for ages 5 to 11 years (orange cap and label border) for either dose 2 or 3</li> </ul> </td> <td> <ul> <li>Do not repeat dose 2 or 3.</li> <li>If the error occurred with dose 2, administer the bivalent Pfizer-BioNTech product for ages 6 months to 4 years (maroon cap and label border) for the third dose at least 8 weeks after the second dose.</li> </ul> </td> </tr> <tr> <td rowspan="2">Product and dosage</td> <td> <ul> <li>Higher-than-authorized dose administered (eg, incorrect dose volume, incorrect product resulting in higher-than-authorized dose)</li> </ul> </td> <td> <ul> <li>Do not repeat <span class="nowrap_whitespace">dose.<sup>¶</sup><sup>Δ</sup></span></li> </ul> </td> </tr> <tr> <td> <ul> <li>Lower-than-authorized dose administered (eg, leaked out of the syringe, equipment failure, recipient pulled away, incorrect product resulting in lower-than-authorized dose)</li> </ul> </td> <td> <ul> <li>Repeat dose immediately (no minimum <span class="nowrap_whitespace">interval).<sup>Δ</sup><sup>◊</sup></span></li> <li>However, if a half-volume dose of vaccine is administered to a patient recommended for the full volume, another half-volume dose can be administered on the same clinic day, and the 2 doses can count as 1 full dose.</li> </ul> </td> </tr> <tr class="highlight_lght_gray_text"> <td rowspan="2">Storage and handling</td> <td> <ul> <li>Dose administered after improper storage and handling (ie, temperature excursion)</li> </ul> </td> <td> <ul> <li>Contact the manufacturer for information on the stability of the <span class="nowrap_whitespace">vaccine.<sup>§</sup></span> If the manufacturer does not have data to support the stability of the vaccine, repeat the dose immediately (no minimum <span class="nowrap_whitespace">interval).<sup>◊</sup></span></li> </ul> </td> </tr> <tr class="highlight_lght_gray_text"> <td> <ul> <li>Dose administered past the expiration/beyond-use date</li> </ul> </td> <td> <ul> <li>Contact the manufacturer for information on the stability of the <span class="nowrap_whitespace">vaccine.<sup>§</sup></span> If the manufacturer does not have data to support the stability of the vaccine, repeat the dose immediately (no minimum <span class="nowrap_whitespace">interval).<sup>◊</sup></span></li> </ul> </td> </tr> <tr> <td rowspan="2">Intervals</td> <td> <ul> <li>Any COVID-19 dose administered prior to the minimum <span class="nowrap_whitespace">interval<sup>¥</sup></span></li> </ul> </td> <td> <ul> <li>Repeat dose. Space repeat dose after the dose given in error by at least the minimum <span class="nowrap_whitespace">interval.<sup>◊</sup></span></li> </ul> </td> </tr> <tr> <td> <ul> <li>Any COVID-19 vaccine dose administered at any interval after the recommended interval</li> </ul> </td> <td> <ul> <li>Do not repeat dose. There is no maximum interval.</li> <li>This deviation from CDC guidance does not require VAERS reporting.</li> </ul> </td> </tr> <tr class="highlight_lght_gray_text"> <td>Interchangeability</td> <td> <ul> <li>COVID-19 vaccines from different manufacturers are administered to: <ul> <li>Children ages 6 months to 5 years who are unvaccinated</li> <li>Children ages 6 months to 4 years who received 1 or more doses of a monovalent mRNA vaccine</li> </ul> </li> </ul> </td> <td> <ul> <li>Do not repeat dose.</li> <li>Any combination of the recommended number of doses is considered valid.</li> </ul> </td> </tr> <tr> <td rowspan="6">Diluent (Pfizer-BioNTech COVID-19 Vaccine formulation only [orange cap and maroon cap])</td> <td> <ul> <li><strong>Only</strong> diluent administered (ie, sterile 0.9% sodium chloride)</li> </ul> </td> <td> <ul> <li>Administer the authorized dose immediately (no minimum interval).</li> </ul> </td> </tr> <tr> <td> <ul> <li>No diluent, resulting in higher than authorized dose</li> </ul> </td> <td> <ul> <li>Do not repeat <span class="nowrap_whitespace">dose.<sup>¶</sup></span> Inform the recipient of the potential for local and systemic adverse events.</li> </ul> </td> </tr> <tr> <td> <ul> <li>Incorrect diluent type (eg, sterile water, bacteriostatic 0.9% sodium chloride)</li> </ul> </td> <td> <ul> <li>Contact the manufacturer for information on the stability of the <span class="nowrap_whitespace">vaccine.<sup>§</sup></span> If the manufacturer does not have information to support the stability of the vaccine, repeat the dose immediately (no minimum <span class="nowrap_whitespace">interval).<sup>◊</sup></span></li> </ul> </td> </tr> <tr> <td> <ul> <li>Vaccine is mixed with too little diluent</li> </ul> </td> <td> <ul> <li>Do not repeat dose. Inform the recipient of the potential for local and systemic adverse <span class="nowrap_whitespace">events.<sup>¶</sup></span></li> </ul> </td> </tr> <tr> <td> <ul> <li>Vaccine is mixed with too much diluent</li> </ul> </td> <td> <ul> <li>Repeat dose immediately (no minimum <span class="nowrap_whitespace">interval).<sup>◊</sup></span></li> </ul> </td> </tr> <tr> <td> <ul> <li>Single-use vial of diluent is used to mix multiple vials of vaccine</li> </ul> </td> <td> <ul> <li>Do not repeat dose. Inform patient of the potential for bacterial infection.</li> </ul> </td> </tr> <tr class="highlight_lght_gray_text"> <td>Diluent (Pfizer-BioNTech COVID-19 formulation that should not be mixed with diluent, ie, gray cap)</td> <td> <ul> <li>Vaccine is mixed with any diluent (ie, any type or volume of diluent)</li> </ul> </td> <td> <ul> <li>Contact the manufacturer for information on the stability of the <span class="nowrap_whitespace">vaccine.<sup>§</sup></span> If the manufacturer does not have information to support the stability of the vaccine, repeat the dose immediately (no minimum <span class="nowrap_whitespace">interval).<sup>◊</sup></span></li> </ul> </td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>CDC: United States Centers for Disease Control and Prevention; 
        VAERS: Vaccine Adverse Event Reporting System; 
        FDA: US Food and Drug Administration; 
        EUA: emergency use authorization.</p>
<p>* Do not administer the second dose until the person becomes eligible to receive vaccination (either by reaching the authorized age or if the authorization is extended to include additional age groups), even if this results in the second dose being administered after the recommended interval between doses. In addition to the minimum age, some experts suggest delaying the second dose for 8 weeks after the invalid dose based on the potential for increased reactogenicity and the rare risk of myocarditis and pericarditis from mRNA COVID-19 vaccine.</p>
<p>¶ If the administration error resulted in a higher-than-authorized vaccine dose, in general a subsequent dose may still be administered at the recommended interval. However, if local or systemic side effects following vaccination are clinically concerning (outside of the expected side effect profile), lead to serious adverse reactions, or are ongoing at the time of the subsequent dose, this dose might be delayed, but this decision should be assessed on a case-by-case basis.</p>
<p>Δ FDA authorization allows for dosing options for certain situations where a child ages from a younger to older age group; see <a href="https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#transitioning-younger-older" target="_blank">Transitioning from a younger to older age group</a>. If the dosing is in accordance with the FDA EUA, it is not considered an error and VAERS reporting is not indicated.</p>
<p>◊ Some experts suggest delaying the repeat dose for 8 weeks after the invalid dose based on the potential for increased reactogenicity and the rare risk of myocarditis and pericarditis from mRNA (Moderna or Pfizer-BioNTech) and Novavax COVID-19 vaccines, particularly in groups at increased risk for myocarditis and pericarditis (eg, males ages 12 to 39 years). Individual risk for COVID-19 and the likelihood for an adverse event following vaccination should be taken into consideration when recommending a longer interval. It is acceptable to administer the repeat dose at an interval earlier than 8 weeks if the interval is not sooner than the minimal interval noted in this table.</p>
    
    § As of the date of this update, current manufacturer contact information is:
    <ul>
<li>Pfizer: 1-877-VAX-CO19 (1-877-829-2619)</li>
<li>Moderna: 1-866-MODERNA (1-866-663-3762)</li>
<li>Janssen: US Toll Free: 1-800-565-4008; US Toll: 1-908-455-9922</li>
<li>Novavax: 1-844-NOVAVAX (1-844-668-2829)</li>
</ul>
<p class="extra_spacing">Please see the <a href="https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines" target="_blank">package inserts</a> and <a href="https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines" target="_blank">EUA provider factsheets</a> for the most up-to-date manufacturer information.</p>
    
    ¥ Vaccine doses administered up to 4 days before the minimum interval may be counted and do not need to be repeated.</div><div class="graphic_reference">Reproduced from: Centers for Disease Control and Prevention. Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendices, References, and Previous Updates. Available at: <a href="https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html" target="_blank">https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html</a> (Accessed on April 27, 2023).</div><div id="graphicVersion">Graphic 130956 Version 12.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
